Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%
Earnings

Cipher Pharmaceuticals to release Q3 results Nov. 6

By The Northwire Desk — AI Analysis Oct 29, 2025 · 21:08 CPH · 14.26 Cipher Pharmaceuticals Inc
CPH · Price

Executive Summary

  • Cipher Pharmaceuticals Inc. will announce its Q3 2025 financial results after market close on Thursday, Nov. 6, 2025.
  • A conference call to discuss the results and corporate developments is scheduled for Friday, Nov. 7, 2025 at 8:30 a.m. ET.
  • Call details, replay numbers, and webcast information are provided for investors and analysts.

Key Details

  • Earnings Release Date: Thursday, Nov. 6, 2025 (after market close).
  • Conference Call Date & Time: Friday, Nov. 7, 2025 at 8:30 a.m. ET.
  • Dial‑in Numbers: 416‑945‑7677 or 888‑699‑1199.
  • Replay Numbers: 289‑819‑1450 or 888‑660‑6345 (expires Nov. 14, 2025).
  • Access Code: 24367 followed by the pound key.
  • Webcast: Available online; link to be provided in the company’s investor relations portal.

Notable Quotes

(No quotes were included in the release.)

Read the original news release →

More from Cipher Pharmaceuticals Inc

May 07, 2026 · 17:00

Cipher Goes Debt-Free and Boasts $71M in Dry Powder, But Stagnant Sales Raise the Bar for Deal-Driven Growth

Earnings May 01, 2026 · 07:00

Cipher Pharmaceuticals NCIB Announcement

Other Mar 12, 2026 · 17:00

Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings

Earnings Mar 04, 2026 · 17:00

Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call

Earnings Jan 28, 2026 · 17:51

Cipher Pharmaceuticals gets Health Canada NDS review

Regulatory Jan 28, 2026 · 08:30

Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba(TM) (Spinosad)

Regulatory